Mucosal response of inactivated and recombinant COVID-19 vaccines in Congolese individualsIMMUNITY INFLAMMATION AND DISEASEIF2.72023-12-271OA
Saliva as a tool for SARS-CoV-2 genomic and immunological surveillance in the Republic of CongoBMJ GLOBAL HEALTHIF6.12023-12-170OA
Saliva and Plasma Antibody Levels in Children and Adolescents After Primary Infection With Omicron Variants of SARS-CoV-2 Infection in GermanyJAMA PEDIATRICSIF182023-06-012OA
Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron VariantsCLINICAL INFECTIOUS DISEASESIF7.32022-07-157OAAI
SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After VaccinationFRONTIERS IN IMMUNOLOGYIF5.92021-12-0924OAAI
Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young ChildrenFRONTIERS IN IMMUNOLOGYIF5.92021-10-0812OAAI
Complementary methods for SARS-CoV-2 diagnosis in times of material shortageSCIENTIFIC REPORTSIF3.92021-06-079OAAI
Immune response to SARS-CoV-2 variants of concern in vaccinated individualsNATURE COMMUNICATIONSIF15.72021-05-2591OAAI